Endo International PLC (NASDAQ:ENDP) Rating Reiterated by Oppenheimer Holdings, Inc.

Endo International PLC (NASDAQ:ENDP)‘s stock had its “hold” rating reaffirmed by equities researchers at Oppenheimer Holdings, Inc. in a report released on Sunday.

Other analysts have also recently issued reports about the stock. Vetr upgraded shares of Endo International PLC from a “hold” rating to a “buy” rating and set a $11.34 target price for the company in a report on Tuesday, May 9th. Mizuho restated a “buy” rating and set a $18.00 target price (up from $17.00) on shares of Endo International PLC in a report on Thursday, April 13th. Deutsche Bank AG reduced their target price on shares of Endo International PLC from $18.00 to $15.00 and set a “buy” rating for the company in a report on Friday, July 7th. BMO Capital Markets restated a “hold” rating and set a $16.00 target price on shares of Endo International PLC in a report on Wednesday, May 17th. Finally, Canaccord Genuity set a $14.00 target price on shares of Endo International PLC and gave the stock a “hold” rating in a report on Thursday, May 11th. Two investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating and six have issued a buy rating to the company’s stock. Endo International PLC presently has a consensus rating of “Hold” and a consensus price target of $17.33.

Endo International PLC (ENDP) traded down 3.2003% during midday trading on Friday, reaching $11.9838. The company had a trading volume of 290,713 shares. Endo International PLC has a 52-week low of $9.70 and a 52-week high of $24.93. The company’s 50 day moving average is $11.73 and its 200-day moving average is $12.05. The company’s market capitalization is $2.67 billion.

Endo International PLC (NASDAQ:ENDP) last issued its earnings results on Tuesday, May 9th. The company reported $1.23 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.10 by $0.13. The firm had revenue of $1.04 billion during the quarter, compared to analysts’ expectations of $1.02 billion. Endo International PLC had a negative net margin of 82.93% and a positive return on equity of 25.32%. The firm’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same period last year, the firm posted $1.08 earnings per share. Equities analysts expect that Endo International PLC will post $3.55 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Endo International PLC (NASDAQ:ENDP) Rating Reiterated by Oppenheimer Holdings, Inc.” was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://sportsperspectives.com/2017/07/24/endo-international-plc-nasdaqendp-rating-reiterated-by-oppenheimer-holdings-inc.html.

Several large investors have recently modified their holdings of ENDP. Amalgamated Bank raised its stake in shares of Endo International PLC by 2.0% in the first quarter. Amalgamated Bank now owns 32,357 shares of the company’s stock worth $361,000 after buying an additional 619 shares during the period. Meeder Asset Management Inc. raised its stake in shares of Endo International PLC by 1.4% in the second quarter. Meeder Asset Management Inc. now owns 48,699 shares of the company’s stock worth $544,000 after buying an additional 677 shares during the period. Capstone Asset Management Co. raised its stake in shares of Endo International PLC by 3.1% in the second quarter. Capstone Asset Management Co. now owns 32,035 shares of the company’s stock worth $358,000 after buying an additional 960 shares during the period. Point View Wealth Management Inc. raised its stake in shares of Endo International PLC by 12.3% in the first quarter. Point View Wealth Management Inc. now owns 11,431 shares of the company’s stock worth $128,000 after buying an additional 1,254 shares during the period. Finally, Oakbrook Investments LLC raised its stake in shares of Endo International PLC by 8.2% in the second quarter. Oakbrook Investments LLC now owns 17,100 shares of the company’s stock worth $191,000 after buying an additional 1,300 shares during the period. 93.15% of the stock is owned by institutional investors.

Endo International PLC Company Profile

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Analyst Recommendations for Endo International PLC (NASDAQ:ENDP)

Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply